JPWO2022053652A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022053652A5 JPWO2022053652A5 JP2023516079A JP2023516079A JPWO2022053652A5 JP WO2022053652 A5 JPWO2022053652 A5 JP WO2022053652A5 JP 2023516079 A JP2023516079 A JP 2023516079A JP 2023516079 A JP2023516079 A JP 2023516079A JP WO2022053652 A5 JPWO2022053652 A5 JP WO2022053652A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077233P | 2020-09-11 | 2020-09-11 | |
| US63/077,233 | 2020-09-11 | ||
| PCT/EP2021/075012 WO2022053652A1 (en) | 2020-09-11 | 2021-09-10 | Combination therapy for cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540618A JP2023540618A (ja) | 2023-09-25 |
| JP2023540618A5 JP2023540618A5 (https=) | 2024-09-17 |
| JPWO2022053652A5 true JPWO2022053652A5 (https=) | 2024-09-17 |
Family
ID=78073883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516079A Pending JP2023540618A (ja) | 2020-09-11 | 2021-09-10 | 癌の併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230364230A1 (https=) |
| EP (1) | EP4211168A1 (https=) |
| JP (1) | JP2023540618A (https=) |
| KR (1) | KR20230066586A (https=) |
| CN (1) | CN116601171A (https=) |
| AU (1) | AU2021339005A1 (https=) |
| CA (1) | CA3191282A1 (https=) |
| IL (1) | IL301048A (https=) |
| MX (1) | MX2023002852A (https=) |
| WO (1) | WO2022053652A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026022712A1 (en) * | 2024-07-23 | 2026-01-29 | Sanofi | Cereblon ligase modulator and bcma nk cell engager combination therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101615935B1 (ko) | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도 |
| US9273136B2 (en) | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
| EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2020033630A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
-
2021
- 2021-09-10 WO PCT/EP2021/075012 patent/WO2022053652A1/en not_active Ceased
- 2021-09-10 CA CA3191282A patent/CA3191282A1/en active Pending
- 2021-09-10 MX MX2023002852A patent/MX2023002852A/es unknown
- 2021-09-10 US US18/044,730 patent/US20230364230A1/en active Pending
- 2021-09-10 JP JP2023516079A patent/JP2023540618A/ja active Pending
- 2021-09-10 EP EP21786092.3A patent/EP4211168A1/en active Pending
- 2021-09-10 IL IL301048A patent/IL301048A/en unknown
- 2021-09-10 KR KR1020237011801A patent/KR20230066586A/ko active Pending
- 2021-09-10 AU AU2021339005A patent/AU2021339005A1/en not_active Abandoned
- 2021-09-10 CN CN202180062423.4A patent/CN116601171A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101420978B (zh) | 通过三官能双特异性抗体破坏表达低至中等水平的肿瘤相关靶抗原的肿瘤细胞 | |
| AU2016378721B2 (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer | |
| Hammer | CD19 as an attractive target for antibody-based therapy | |
| US20220226469A1 (en) | Therapeutic sirp-alpha antibodies | |
| CN105012953B (zh) | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 | |
| JP2020504723A5 (https=) | ||
| Strohl | Structure and function of therapeutic antibodies approved by the US FDA in 2023 | |
| JP2020516309A5 (https=) | ||
| US20220411512A1 (en) | Combination treatment for cancer | |
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| Shui et al. | Bispecific antibodies: unleashing a new era in oncology treatment | |
| JP7712925B2 (ja) | 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ | |
| Robak et al. | Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia | |
| US20250340634A1 (en) | Dosage regimens for anti-cd19 agents and uses thereof | |
| Pandey et al. | Monoclonal antibodies as therapeutics in human malignancies | |
| JP2025175307A (ja) | 逐次抗ｃｄ１９治療 | |
| TW202104263A (zh) | 雙特異性CD123xCD3雙抗體在血液系統惡性腫瘤治療中的給藥方案 | |
| Quintás-Cardama et al. | Investigational immunotherapeutics for B-cell malignancies | |
| JPWO2022053652A5 (https=) | ||
| JPWO2022097061A5 (https=) | ||
| US11814436B2 (en) | Anti-CD30 monoclonal antibodies and chimeric antigen receptors | |
| JPWO2020222668A5 (https=) | ||
| JP2026513536A (ja) | 安定性が改善されたｉｌ－２バリアント及びその組成物 | |
| TW202432175A (zh) | 治療癌症之組合療法 | |
| RU2023130537A (ru) | Введение доз для лечения биспецифическим антителом к cd20/cd3 |